Compare CVS Health Corp (CVS) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Vanguard S&P 500 ETF — how do they compare? CVS Health Corp trades at $93.7 (market cap $122.36B), while Vanguard S&P 500 ETF trades at $709.04. The key difference: CVS Health Corp pays a 2.78% dividend while Vanguard S&P 500 ETF pays none, and Vanguard S&P 500 ETF is trading nearer its 52-week high, CVS Health Corp nearer its low. Which is the better fit depends on your goals.
| CVS | VOO | |
|---|---|---|
Market Cap | $122.36B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $110.60 | $710.71 |
52-Week Low | $65.51 | $580.93 |
Enterprise Value | $184.71B | — |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
VOO (Vanguard S&P 500 ETF) trades at $710.71, up 0.6% with a bullish technical signal from moving averages. The ETF tracks the S&P 500 index, which recently reclaimed record highs amid strong corporate earnings and AI-driven optimism. Technical indicators show overbought conditions with RSI at 94.45 on the 6-day timeframe, while support levels begin at $708. JPMorgan raised its S&P 500 year-end target to 8,000, citing earnings strength and AI investment payoffs.
The outlook remains positive given robust earnings growth and institutional confidence, though near-term consolidation risks exist from overbought technicals and valuation concerns. Key risks include market breadth weakness and potential September volatility. The ETF's low-cost structure and diversification continue to attract long-term investors seeking S&P 500 exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
